Found: 16
Select item for more details and to access through your institution.
Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2450, doi. 10.1111/dom.13826
- By:
- Publication type:
- Article
Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1837, doi. 10.1111/dom.13739
- By:
- Publication type:
- Article
Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 3, p. 525, doi. 10.1111/dom.13547
- By:
- Publication type:
- Article
Liraglutide and Glycaemic Outcomes in the LEADER Trial.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 6, p. 2383, doi. 10.1007/s13300-018-0524-z
- By:
- Publication type:
- Article
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01949-7
- By:
- Publication type:
- Article
Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 7, p. 1, doi. 10.1007/s11095-020-02817-9
- By:
- Publication type:
- Article
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
- Published in:
- Nephrology Dialysis Transplantation, 2023, v. 38, n. 9, p. 2041, doi. 10.1093/ndt/gfad009
- By:
- Publication type:
- Article
Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2021, v. 14, p. 2619, doi. 10.2147/DMSO.S305496
- By:
- Publication type:
- Article
A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
- Published in:
- Journal of Diabetes Investigation, 2022, v. 13, n. 8, p. 1321, doi. 10.1111/jdi.13789
- By:
- Publication type:
- Article
European regulation on orphan medicinal products: 10 years of experience and future perspectives.
- Published in:
- 2011
- By:
- Publication type:
- review
Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of a phase 3 randomized clinical trial.
- Published in:
- Journal of Diabetes Investigation, 2018, v. 9, n. 4, p. 840, doi. 10.1111/jdi.12793
- By:
- Publication type:
- Article
Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial
- Published in:
- Journal of Diabetes Investigation, 2018, v. 9, n. 4, p. 831, doi. 10.1111/jdi.12759
- By:
- Publication type:
- Article
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 4, p. 565, doi. 10.1111/jdi.12457
- By:
- Publication type:
- Article
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallelgroup trial.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 1, p. 76, doi. 10.1111/jdi.12367
- By:
- Publication type:
- Article
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article